Every 10-Q that Cadrenal Therapeutics, Inc. (CVKD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company developing CAD-1005, tecarfarin and frunexian for critical care cardiology and orphan cardiovascular conditions. For the six months ended June 30, 2026, it reported a net loss of $5.8 million, an improvement from $7.5 million a year earlier, as total operating expenses fell 24% to $5.9 million. Cash used in operations was $5.2 million.
At June 30, 2026, Cadrenal held $2.4 million in cash and cash equivalents, total assets of $5.6 million and stockholders’ equity of $4.1 million, with an accumulated deficit of $44.8 million. Management states that expected operating losses and capital needs will exceed existing cash, raising substantial doubt about its ability to continue as a going concern without additional financing. The company raised capital through an April 2026 warrant exercise and a June 2026 PIPE and is pursuing further equity, debt, grants and partnerships while prioritizing early- to mid-stage validation and out-licensing rather than self-funding Phase 3 trials.
Cadrenal Therapeutics reported a Q1 2026 net loss of $2.5 million, narrower than $3.8 million a year earlier, as operating expenses fell 36% to $2.5 million. Cash and cash equivalents were $2.3 million with net cash used in operations of $3.0 million, raising substantial doubt about its ability to continue as a going concern.
The late-stage biopharma is prioritizing lead candidate CAD-1005 for heparin-induced thrombocytopenia and plans a Phase 3 trial targeting an NDA submission in 2029. Stockholders’ equity of $1.8 million fell below Nasdaq’s $2.5 million requirement, though a subsequent $2.5 million warrant exercise in April 2026 is expected to bolster equity.
Cadrenal Therapeutics (CVKD) reported a larger year-to-date loss and flagged liquidity risk. Net loss was $2.69 million for Q3 2025 and $10.20 million for the nine months ended September 30, 2025. Operating expenses for the nine months rose to $10.40 million, driven by higher G&A of $6.96 million (up 73%) and R&D of $3.43 million (up 29%). Interest and dividend income contributed $0.20 million year to date.
Cash and cash equivalents were $3.86 million as of September 30, 2025, after $10.03 million used in operating activities year to date. Management states these factors raise substantial doubt about the company’s ability to continue as a going concern. To bolster liquidity, Cadrenal raised $3.83 million net via its ATM during the nine months and a further approximately $0.22 million net after quarter-end.
On September 12, 2025, Cadrenal acquired eXIthera assets, including frunexian (EP-7041) and EP-7327. The company paid $50,000 at closing and expensed $151,216 in transaction costs, with contingent milestones of up to $15 million, a 2% royalty on future net sales, and 50% of royalties received under the Haisco license.
Cadrenal Therapeutics (CVKD) reported unaudited results for the quarter ended June 30, 2025 showing a quarterly net loss of $3.67 million and a six‑month net loss of $7.51 million. Cash and cash equivalents were $5.57 million at June 30, 2025 and approximately $5.0 million as of August 6, 2025, which the company states is expected to fund operations for at least the next twelve months from the filing date. Working capital was about $4.3 million and the accumulated deficit stood at $33.2 million. As of August 11, 2025, there were 2,046,854 shares outstanding.
Operating expenses increased year‑over‑year: six‑month general and administrative expenses rose to $4.91 million (110% increase) and research and development expenses rose to $2.75 million (46% increase) driven by CMC, personnel and clinical preparation costs. Financing activity included $3.35 million gross ATM proceeds in H1 2025 and an additional ~$516,000 gross via ATM in July 2025. Tecarfarin holds orphan and fast‑track designations for specified indications and the company announced clinical trial initiation plans for ESKD patients transitioning to dialysis on August 5, 2025.